Stevens Capital Management LP purchased a new position in shares of Akorn, Inc. (NASDAQ:AKRX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 71,385 shares of the company’s stock, valued at approximately $927,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. grew its holdings in Akorn by 3.0% during the first quarter. Principal Financial Group Inc. now owns 397,685 shares of the company’s stock worth $7,441,000 after purchasing an additional 11,468 shares during the period. Aperio Group LLC grew its holdings in Akorn by 83.4% during the second quarter. Aperio Group LLC now owns 58,778 shares of the company’s stock worth $975,000 after purchasing an additional 26,734 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in Akorn during the second quarter worth about $1,103,000. NJ State Employees Deferred Compensation Plan bought a new position in Akorn during the second quarter worth about $199,000. Finally, Alps Advisors Inc. grew its holdings in Akorn by 7.5% during the second quarter. Alps Advisors Inc. now owns 180,583 shares of the company’s stock worth $2,996,000 after purchasing an additional 12,584 shares during the period. Institutional investors and hedge funds own 65.00% of the company’s stock.
Shares of AKRX stock opened at $4.26 on Friday. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 1.26. Akorn, Inc. has a 12-month low of $3.54 and a 12-month high of $33.63.
Several equities research analysts have issued reports on the stock. Deutsche Bank restated a “buy” rating on shares of Akorn in a research report on Thursday, August 23rd. BidaskClub upgraded shares of Akorn from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 6th. Zacks Investment Research upgraded shares of Akorn from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Monday, August 27th. Piper Jaffray Companies set a $9.00 price objective on shares of Akorn and gave the stock a “buy” rating in a research report on Tuesday, November 27th. Finally, Royal Bank of Canada set a $9.00 price objective on shares of Akorn and gave the stock a “hold” rating in a research report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $14.67.
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Featured Story: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding AKRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akorn, Inc. (NASDAQ:AKRX).
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.